Phase III trial comparing dexamethasone (DEX) to the combination of DEX + CC-5013 in patients with previously untreated multiple myeloma.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Nov 2010 Primary endpoint 'Progression-free-survival-rate' has been met
- 24 Nov 2010 Status changed from active, no longer recruiting to completed.
- 27 Sep 2010 Results were published in Blood.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History